Publications by authors named "I Garrido-Laguna"
This first-in-human study evaluated safety and efficacy of CD40 agonist MEDI5083 with durvalumab in patients with advanced solid tumors. Patients received MEDI5083 (3-7.5 mg subcutaneously every 2 weeks × 4 doses) and durvalumab (1500 mg every 4 weeks) either sequentially (N = 29) or concurrently (N = 9).
View Article and Find Full Text PDFArticle Synopsis
- - Determining the best treatment plan for rectal cancer is complicated, involving choices between curative or palliative surgery and considering impact on bowel function and quality of life, especially for distal rectal cancer patients.
- - Patients with rectal cancer face a higher risk of pelvic recurrence compared to those with colon cancer, making careful patient selection and a multidisciplinary treatment approach essential for better outcomes.
- - Recent updates to the NCCN Guidelines for Rectal Cancer include new treatment options like endoscopic submucosal dissection for early cases, revisions to the total neoadjuvant therapy strategy, and a nonoperative "watch-and-wait" option for patients who respond well to initial therapy.
Article Synopsis
- Colorectal cancer (CRC) ranks as the fourth most common cancer and the second deadliest in the U.S.
- Treatment for advanced metastatic CRC includes multiple active drugs used alone or in combination, depending on patient-specific factors.
- The paper reviews the systemic therapy recommendations for metastatic CRC as outlined in the NCCN Guidelines for Colon Cancer.
Article Synopsis
- - This study focuses on undifferentiated sarcomatoid carcinoma (USC), a rare and aggressive subtype of pancreatic ductal adenocarcinoma (PDAC), and aims to identify potential biomarkers for targeted therapies based on genomic profiling.
- - 20 USC tumors were analyzed alongside over 5,500 non-USC PDAC tumors, revealing that USC tumors had a significantly higher prevalence of PD-L1 expression and an increase in specific immune cells compared to non-USC tumors.
- - The study concludes that USC tumors show increased expression of immune checkpoint genes, suggesting a potential for targeted treatment with immune checkpoint inhibitors, warranting further research.